• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Imaging and Intervention

Multiple-electrode switching radiofrequency ablation may successfully treat lung tumors

byBenjamin Laguna, MDandDylan Wolman
June 12, 2015
in Imaging and Intervention, Oncology, Pulmonology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Radiofrequency ablation with a multiple-electrode switching system can safely be used to successfully treat lung tumors 2-5 cm in size in nonsurgical candidates.

Evidence Rating Level: 4 (Below-Average)

Study Rundown: Patients with non-surgical lung tumors face limited treatment options, many of which are often accompanied by a high risk of morbidity and mortality. Radiofrequency ablation (RFA) has been shown to be effective in decreasing the size of small lung tumors, but has not been as successful in the treatment of larger tumors, with increased rates of local recurrence as compared to other modalities. Multiple-electrode switching RFA systems can increase the overall ablative zone volume through sequential switching of power between electrodes, which would be particularly useful in larger tumors. The current study is a phase II clinical trial demonstrating that RFA using a multiple-electrode switching system can be a safe alternative treatment for non-surgical lung tumors with low recurrence rates and morbidity similar to that of standard RFA systems. Using between 2 and 3 RF electrode arrays, technical success was achieved in all patients, while 1-year tumor progression rates were 12.7%. Significant complications occurred in 12% of patients, including pleuritis, pneumothorax and pulmonary hemorrhage, though no procedure-related deaths occurred. This study provides evidence of a safe, new treatment for non-surgical lung tumor patients, increasing the viable options for such patients. The relatively small size and lack of patient-controls are the most significant limitations, in addition to the relatively short follow-up period of only 1 year. Future studies should examine this technique in a larger population, and may benefit from randomized controlled trial design to compare multiple-electrode switching RFA systems to other treatment modalities, such as body radiation therapy, or pulmonary resection.

Click to read the study in American Journal of Roentgenology

Relevant reading: Lung radiofrequency ablation for the treatment of unresectable recurrent non-small-cell lung cancer after surgical intervention.

In-Depth [case series]: A total of 33 patients (78% male with mean age 70.5 ± 10 years) from a single medical center with nonsurgical lung tumors sized 2.0 – 5.0 cm were included in the trial. These patients were not matched to controls. All patients had fewer than 3 tumors, with a total of 51 treated tumors, 35 of which were treated with multiple electrode switching RFA. These 35 tumors were evaluated for size, response to treatment, adverse events, and recurrence. Among these 35 tumors, the mean diameter was 3.0 cm +/- 0.7 (range, 2-4.4 cm.) Tumors were primarily non-small cell lung cancer (51%), while the remainder were metastases (49%). There were no deaths or grade 4 adverse events at the time of procedure, though 12% of patients had grade 3 adverse events including pulmonary hemorrhage, pneumothorax and aseptic pleuritis, and 39% experienced grade 2 adverse events including minor pneumothorax or pneumonitis. Overall, the rate of one-year local tumor progression was 12.7% (95% CI: 1.0-25.5) with a one-year survival rate of 81.2% (95% CI: 67.6-94.8). The survival rate was insignificantly higher in those primary lung cancer than in those with metastatic lung cancer, at 82.4% versus 79.4% (p = 0.25), though univariate analysis revealed that prognoses were poorer with tumors larger than 3.0 cm (p = 0.04) and if extrapulmonary tumors were present (p = 0.03).

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Fleischner Society Guidelines, 2005 Statement: Limited CT follow-up recommended for small, solitary, pulmonary nodules [Classics Series]

Neoadjuvant nivolumab with chemotherapy increases survival in resectable non-small-cell lung cancer

#VisualAbstract: Segmentectomy is superior to lobectomy for patients with early-stage non-small cell lung cancer

Tags: lung cancerradiofrequency ablation
Previous Post

US annual incidence of basal cell carcinoma nears 2 million

Next Post

Significant rates of hormone therapy discontinuation in breast cancer patients

RelatedReports

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Radiology Classics

Fleischner Society Guidelines, 2005 Statement: Limited CT follow-up recommended for small, solitary, pulmonary nodules [Classics Series]

June 14, 2022
Surgical site anesthetic infusion may enhance analgesia after mastectomy
Oncology

Neoadjuvant nivolumab with chemotherapy increases survival in resectable non-small-cell lung cancer

May 30, 2022
#VisualAbstract: Increased physical activity is a long-term protective factor for dementia
StudyGraphics

#VisualAbstract: Segmentectomy is superior to lobectomy for patients with early-stage non-small cell lung cancer

May 18, 2022
Quick Take: Intravenous patient-controlled analgesia versus thoracic epidural analgesia after open liver surgery
Chronic Disease

Segmentectomy is superior to lobectomy for patients with early-stage non-small cell lung cancer

May 3, 2022
Next Post
Adjuvant radiation decreases local recurrence in low-risk breast cancer

Significant rates of hormone therapy discontinuation in breast cancer patients

BRAF V600E mutations linked with increased mortality in thyroid cancer

Integrative genomic analysis promising for diagnostic subtyping of lower-grade glioma

Endovascular treatment of intracranial aneurysms prevents long-term recurrence

Endovascular treatment of intracranial aneurysms prevents long-term recurrence

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Treatment of anal high-grade squamous intraepithelial lesions can reduce rates of progression to invasive anal cancer.
  • High tumour mutation burden in NSCLC associated with improved clinical outcomes of PD-L1 blockade across PD-L1 expression subgroups
  • Subsidization of supermarkets may help reduce obesity risk in children
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.